Prevalence, Magnitude, and Correlates of HIV-1 Genital Shedding in Women on Antiretroviral Therapy

Journal of Infectious Diseases

Volumn 216, Issue 12, 2017, Pages 1534-1540

  King, Caroline C ^a   Ellington, Sascha R ^a   Davis, Nicole L ^a   Coombs, Robert W ^b   Pyra, Maria ^b   Hong, Ting ^b   Mugo, Nelly ^b   Patel, Rena C ^b   Lingappa, Jairam R ^b   Baeten, Jared M ^b   Kourtis, Athena P ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

antiretroviral; genital shedding; HIV; viral load

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NEVIRAPINE;

ADULT; AFRICAN; ANTIRETROVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; FEMALE GENITAL TRACT INFECTION; GENITAL ULCER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAGNITUDE ESTIMATION METHOD; MAJOR CLINICAL STUDY; NONHUMAN; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STAGING; TREATMENT DURATION; UTERINE CERVIX DISEASE; VIRUS LOAD; VIRUS SHEDDING; AFRICA; BLOOD; EPIDEMIOLOGY; FEMALE GENITAL SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; VIROLOGY;

ADULT; AFRICA; ANTI-RETROVIRAL AGENTS; BLOOD; FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HIV-1; HUMANS; PREVALENCE; PROSPECTIVE STUDIES; VIRAL LOAD; VIRUS SHEDDING;

EID: 85040088714     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix550     Document Type: Article

References (28)

1. Cohen MS, Chen YQ, McCauley M, et al.; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
2. Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2011; (7):CD003510.
3. Graham SM, Holte SE, Peshu NM, et al. Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 2007; 21:501-7.
4. Cu-Uvin S, DeLong AK, Venkatesh KK, et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010; 24:2489-97.
5. John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001; 183:206-12.
6. Low AJ, Konate I, Nagot N, et al.; Yerelon Study Group. Cervicovaginal HIV-1 shedding in women taking antiretroviral therapy in Burkina Faso: a longitudinal study. J Acquir Immune Defic Syndr 2014; 65:237-45.
7. Tanton C, Weiss HA, Le Goff J, et al. Correlates of HIV-1 genital shedding in Tanzanian women. PLoS One 2011; 6:e17480.
8. Sheth AN, Evans-Strickfaden T, Haaland R, et al. HIV-1 genital shedding is suppressed in the setting of high genital antiretroviral drug concentrations throughout the menstrual cycle. J Infect Dis 2014; 210:736-44.
9. Grignolo S, Bruzzone B, Gabbi L, et al. Vaginal HIV-1 shedding among HIV-1 infected women in the current era of combined antiretroviral therapy: a cross sectional study. Virulence 2017; 8:101-8.
10. Dumond JB, Yeh RF, Patterson KB, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre-and post-exposure prophylaxis. AIDS 2007; 21:1899-907.
11. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: The male and female genital tract. Antivir Ther 2011; 16:1149-67.
12. Kwara A, Delong A, Rezk N, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIVinfected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis 2008; 46:719-25.
13. Reichelderfer PS, Coombs RW, Wright DJ, et al. Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital tract. WHS 001 Study Team. AIDS 2000; 14:2101-7.
14. Heffron R, Donnell D, Rees H, et al.; Partners in Prevention HSV/HIV Transmission Study Team. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012; 12:19-26.
15. Polis CB, Phillips SJ, Curtis KM. Hormonal contraceptive use and female-to-male HIV transmission: a systematic review of the epidemiologic evidence. AIDS 2013; 27:493-505.
16. Baeten JM, Donnell D, Ndase P, et al.; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
17. Celum C, Wald A, Lingappa JR, et al.; Partners in Prevention HSV/HIV Transmission Study Team. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427-39.
18. Neely MN, Benning L, Xu J, et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 44:38-42.
19. Fiore JR, Suligoi B, Saracino A, et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 2003; 17:2169-76.
20. Kovacs A, Wasserman SS, Burns D, et al.; DATRI Study Group; WIHS Study Group. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001; 358:1593-601.
21. Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011; 3:77ra29.
22. Spencer LY, Christiansen S, Wang CH, et al. Systemic immune activation and HIV shedding in the female genital tract. J Acquir Immune Defic Syndr 2016; 71:155-62.
23. Jaspan HB, Liebenberg L, Hanekom W, et al. Immune activation in the female genital tract during HIV infection predicts mucosal CD4 depletion and HIV shedding. J Infect Dis 2011; 204:1550-6.
24. Wang CC, McClelland RS, Reilly M, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 2001; 183:1017-22.
25. Lawn SD, Subbarao S, Wright TC Jr, et al. Correlation between human immunodeficiency virus type 1 RNA levels in the female genital tract and immune activation associated with ulceration of the cervix. J Infect Dis 2000; 181:1950-6.
26. LeGoff J, Weiss HA, Gresenguet G, et al. Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes. AIDS 2007; 21:1569-78.
27. Gitau RW, Graham SM, Masese LN, et al. Effect of acquisition and treatment of cervical infections on HIV-1 shedding in women on antiretroviral therapy. AIDS 2010; 24:2733-7.
28. Kemal KS, Foley B, Burger H, et al. HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A 2003; 100:12972-7.